Krystal Biotech, Inc. operates as a biotechnology company, which engages in developing and commercializing pharmaceutical products. The company is headquartered in Pittsburgh, Pennsylvania and currently employs 275 full-time employees. The company went IPO on 2017-09-20. The firm is focused on the discovery, development, and commercialization of genetic medicines to treat diseases with high unmet medical needs. Its product candidates in various stages of clinical and preclinical development include KB407, KB408, KB707, KB105, KB801, KB803, KB304 and KB301. Its commercial product, VYJUVEK, is a redosable gene therapy, and a genetic medicine approved in the United States and Europe for the treatment of dystrophic epidermolysis bullosa. KB407 is being developed for the treatment of Cystic Fibrosis. KB408 is being developed for the treatment of Alpha-1 Antitrypsin Deficiency, a rare lung disease. KB707 is being developed for the treatment of solid tumors. KB105 is being developed for TGM1-Deficient Autosomal Recessive Congenital Ichthyosis. KB803 is a redosable eye drop formulation of B-VEC, designed for the treatment of ocular complications.
Follow-Up Questions
Krystal Biotech Inc (KRYS)'in P/E oranı nedir?
Krystal Biotech Inc 'in P/E oranı 50.1119 'dir
Krystal Biotech Inc 'in CEO'su kimdir?
Mr. Krish Krishnan 2016 'den beri şirketle birlikte olan Krystal Biotech Inc 'in Chairman of the Board 'ıdır.
KRYS hissesinin fiyat performansı nasıl?
KRYS 'in mevcut fiyatı $160.61 'dir, son işlem günde 0% increased etti.
Krystal Biotech Inc için ana iş temaları veya sektörler nelerdir?
Krystal Biotech Inc Biotechnology endüstrisine ait ve sektör Health Care 'dir
Krystal Biotech Inc 'in piyasa değerlemesi nedir?
Krystal Biotech Inc 'in mevcut piyasa değerlemesi $4.6B 'dir
Krystal Biotech Inc al, sat, yoksa beklemeli mi?
Wall Street analistlerine göre, 13 analist Krystal Biotech Inc için analist derecelendirmeleri gerçekleştirdi, bunlar 6 güçlü al, 10 al, 2 tut, 0 sat ve 6 güçlü sat içermektedir
